Clinical Trials
24 trialsStudy to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
POPLIN
Regeneron Pharmaceuticals
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Rigshospitalet, Denmark
EMBRACE
Ontario Clinical Oncology Group (OCOG)
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
NexCAR19
Health Institutes of Turkey
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
University of Utah
BaseCAR-01
University Hospital, Basel, Switzerland
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
PACER
Ann & Robert H Lurie Children's Hospital of Chicago
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Case Comprehensive Cancer Center
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Case Comprehensive Cancer Center
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
Masonic Cancer Center, University of Minnesota
MR-ICANS
University Hospital, Montpellier
Rhu-pGSN for Severe Covid-19 Pneumonia
BioAegis Therapeutics Inc.
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Chinese PLA General Hospital
ULTRA-COVID
Fundacion GenesisCare
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
GlaxoSmithKline